181 related articles for article (PubMed ID: 38750040)
1. Simulating BRAFV600E-MEK-ERK signalling dynamics in response to vertical inhibition treatment strategies.
De Carli A; Kapelyukh Y; Kursawe J; Chaplain MAJ; Wolf CR; Hamis S
NPJ Syst Biol Appl; 2024 May; 10(1):51. PubMed ID: 38750040
[TBL] [Abstract][Full Text] [Related]
2. Quantifying ERK activity in response to inhibition of the BRAFV600E-MEK-ERK cascade using mathematical modelling.
Hamis SJ; Kapelyukh Y; McLaren A; Henderson CJ; Roland Wolf C; Chaplain MAJ
Br J Cancer; 2021 Nov; 125(11):1552-1560. PubMed ID: 34621046
[TBL] [Abstract][Full Text] [Related]
3. Protein Kinase CK2α Maintains Extracellular Signal-regulated Kinase (ERK) Activity in a CK2α Kinase-independent Manner to Promote Resistance to Inhibitors of RAF and MEK but Not ERK in BRAF Mutant Melanoma.
Zhou B; Ritt DA; Morrison DK; Der CJ; Cox AD
J Biol Chem; 2016 Aug; 291(34):17804-15. PubMed ID: 27226552
[TBL] [Abstract][Full Text] [Related]
4. Growth arrest by activated BRAF and MEK inhibition in human anaplastic thyroid cancer cells.
Kurata K; Onoda N; Noda S; Kashiwagi S; Asano Y; Hirakawa K; Ohira M
Int J Oncol; 2016 Dec; 49(6):2303-2308. PubMed ID: 27748799
[TBL] [Abstract][Full Text] [Related]
5. Aberrant modulation of ribosomal protein S6 phosphorylation confers acquired resistance to MAPK pathway inhibitors in BRAF-mutant melanoma.
Gao MZ; Wang HB; Chen XL; Cao WT; Fu L; Li Y; Quan HT; Xie CY; Lou LG
Acta Pharmacol Sin; 2019 Feb; 40(2):268-278. PubMed ID: 29777202
[TBL] [Abstract][Full Text] [Related]
6. Molecular pathways: adaptive kinome reprogramming in response to targeted inhibition of the BRAF-MEK-ERK pathway in cancer.
Johnson GL; Stuhlmiller TJ; Angus SP; Zawistowski JS; Graves LM
Clin Cancer Res; 2014 May; 20(10):2516-22. PubMed ID: 24664307
[TBL] [Abstract][Full Text] [Related]
7. Global view of the RAF-MEK-ERK module and its immediate downstream effectors.
Santini CC; Longden J; Schoof EM; Simpson CD; Jeschke GR; Creixell P; Kim J; Wu X; Turk BE; Rosen N; Poulikakos PI; Linding R
Sci Rep; 2019 Jul; 9(1):10865. PubMed ID: 31350469
[TBL] [Abstract][Full Text] [Related]
8. Concurrent MEK targeted therapy prevents MAPK pathway reactivation during BRAFV600E targeted inhibition in a novel syngeneic murine glioma model.
Grossauer S; Koeck K; Murphy NE; Meyers ID; Daynac M; Truffaux N; Truong AY; Nicolaides TP; McMahon M; Berger MS; Phillips JJ; James CD; Petritsch CK
Oncotarget; 2016 Nov; 7(46):75839-75853. PubMed ID: 27713119
[TBL] [Abstract][Full Text] [Related]
9. Tumor suppressor miR-193a-3p enhances efficacy of BRAF/MEK inhibitors in BRAF-mutated colorectal cancer.
Hiraide S; Takahashi M; Yoshida Y; Yamada H; Komine K; Ishioka C
Cancer Sci; 2021 Sep; 112(9):3856-3870. PubMed ID: 34288281
[TBL] [Abstract][Full Text] [Related]
10. MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition.
Wagle N; Van Allen EM; Treacy DJ; Frederick DT; Cooper ZA; Taylor-Weiner A; Rosenberg M; Goetz EM; Sullivan RJ; Farlow DN; Friedrich DC; Anderka K; Perrin D; Johannessen CM; McKenna A; Cibulskis K; Kryukov G; Hodis E; Lawrence DP; Fisher S; Getz G; Gabriel SB; Carter SL; Flaherty KT; Wargo JA; Garraway LA
Cancer Discov; 2014 Jan; 4(1):61-8. PubMed ID: 24265154
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models.
Del Curatolo A; Conciatori F; Cesta Incani U; Bazzichetto C; Falcone I; Corbo V; D'Agosto S; Eramo A; Sette G; Sperduti I; De Luca T; Marabese M; Shirasawa S; De Maria R; Scarpa A; Broggini M; Del Bufalo D; Cognetti F; Milella M; Ciuffreda L
J Exp Clin Cancer Res; 2018 Jul; 37(1):140. PubMed ID: 29986755
[TBL] [Abstract][Full Text] [Related]
12. BRAF
Dizdar L; Werner TA; Drusenheimer JC; Möhlendick B; Raba K; Boeck I; Anlauf M; Schott M; Göring W; Esposito I; Stoecklein NH; Knoefel WT; Krieg A
Int J Cancer; 2019 Mar; 144(6):1379-1390. PubMed ID: 30144031
[TBL] [Abstract][Full Text] [Related]
13.
Tan J; Liu R; Zhu G; Umbricht CB; Xing M
Proc Natl Acad Sci U S A; 2020 Jul; 117(27):15846-15851. PubMed ID: 32561648
[TBL] [Abstract][Full Text] [Related]
14. MAPK pathway inhibition induces MET and GAB1 levels, priming BRAF mutant melanoma for rescue by hepatocyte growth factor.
Caenepeel S; Cooke K; Wadsworth S; Huang G; Robert L; Moreno BH; Parisi G; Cajulis E; Kendall R; Beltran P; Ribas A; Coxon A; Hughes PE
Oncotarget; 2017 Mar; 8(11):17795-17809. PubMed ID: 28147313
[TBL] [Abstract][Full Text] [Related]
15. Discovery of a Novel ATP-Competitive MEK Inhibitor DS03090629 that Overcomes Resistance Conferred by BRAF Overexpression in BRAF-Mutated Melanoma.
Takano K; Munehira Y; Hatanaka M; Murakami R; Shibata Y; Shida T; Takeuchi K; Takechi S; Tabata T; Shimada T; Kishikawa S; Matsui Y; Ubukata O; Seki T; Kaneta Y
Mol Cancer Ther; 2023 Mar; 22(3):317-332. PubMed ID: 36622773
[TBL] [Abstract][Full Text] [Related]
16. Resistance to BRAF-targeted therapy in melanoma.
Sullivan RJ; Flaherty KT
Eur J Cancer; 2013 Apr; 49(6):1297-304. PubMed ID: 23290787
[TBL] [Abstract][Full Text] [Related]
17. BRAF and MEK inhibition variably affect GD2-specific chimeric antigen receptor (CAR) T-cell function in vitro.
Gargett T; Fraser CK; Dotti G; Yvon ES; Brown MP
J Immunother; 2015 Jan; 38(1):12-23. PubMed ID: 25415284
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of resistance to RAF inhibition in melanomas harboring a BRAF mutation.
Chapman PB
Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714462
[TBL] [Abstract][Full Text] [Related]
19. Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma.
Müller J; Krijgsman O; Tsoi J; Robert L; Hugo W; Song C; Kong X; Possik PA; Cornelissen-Steijger PD; Geukes Foppen MH; Kemper K; Goding CR; McDermott U; Blank C; Haanen J; Graeber TG; Ribas A; Lo RS; Peeper DS
Nat Commun; 2014 Dec; 5():5712. PubMed ID: 25502142
[TBL] [Abstract][Full Text] [Related]
20. BRAF internal deletions and resistance to BRAF/MEK inhibitor therapy.
Johnson DB; Childress MA; Chalmers ZR; Frampton GM; Ali SM; Rubinstein SM; Fabrizio D; Ross JS; Balasubramanian S; Miller VA; Stephens PJ; Sosman JA; Lovly CM
Pigment Cell Melanoma Res; 2018 May; 31(3):432-436. PubMed ID: 29171936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
